Drug intelligence / Profile preview

ODM-106

Development stage: Discontinued
Lead developer: Orion
Modality: Small Molecules
Administration: Oral

Overview

ODM-106 is a small molecule drug developed by Orion for the treatment of essential tremor. It acts as a positive allosteric modulator of the GABA-B receptor, enhancing the activity of this inhibitory neurotransmitter system in the brain. The drug was classified as an antiparkinsonian agent and reached phase 1 clinical trials before its development was discontinued for essential tremor. ODM-106 is orally administered and was investigated for its pharmacokinetics and pharmacodynamics in healthy volunteers[1][2][3].

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on ODM-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODM-106.

Explore the full profile